clinical trial · NCT05119569
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche·phase2·active not recruiting·n = 109
Relapsing Multiple SclerosisFenebrutinibPlacebo
brief summary
This is a study evaluating the effect of fenebrutinib on brain magnetic resonance imaging (MRI) in participants with RMS. The safety and pharmacokinetics of fenebrutinib will also be evaluated. Participants will be randomized to receive either fenebrutinib or placebo. This study consists of two parts: Double-blind treatment (DBT) phase and an optional Open-label extension (OLE) phase.
started
Mar 1, 2022
primary completion
Mar 29, 2023
completion
Dec 30, 2026
last updated
Feb 4, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol